Immuno-Hématologie Clinique - Hôpitaux Sud

Recherches :

 

L’activité de Recherche Clinique est réalisée en partenariat avec l’Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), l’Assistance Publique - Hôpitaux de Marseille, et l’Industrie Pharmaceutique.

 

Cette activité de recherche s’appuie sur un Département de Recherche Clinique doté d’un personnel dédié formé aux bonnes pratiques cliniques  comprenant deux médecins seniors, un Moniteur d’Etudes Cliniques (ANRS), cinq ingénieurs de recherche.
 
Elle est développée autour de différentes thématiques :

• l’évaluation de nouvelles molécules pour le traitement de l’infection par le VIH et des hépatites virales B et C. L’accès à ces traitements est ainsi facilité pour les patients en situation d’échec thérapeutique
• le réservoir viral et la reconstitution immunitaire sous traitement antirétroviral efficace et les mécanisme impliqués dans la persistance d’une activation immunitaire délétère
• l’exploration et la gestion des co-morbidités secondaires au virus VIH et aux thérapeutiques antirétrovirales
• le dépistage/diagnostic précoce des cancers (col, canal anal, poumon, …)

 

L’unité est par ailleurs centre national pour la recherche vaccinale anti VIH chez les volontaires sains depuis 2001.

 

Principales publications dans les différentes thématiques de recherche :

 

2018

 

• C SOLAS, S BREGIGEON, O FAUCHER-ZAEGEL, S QUARANTA, V OBRY-ROGUET, C TAMALET, B LACARELLE, I POIZOT-MARTIN Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety. Br J Clin Pharmacol.  2018;84:404-409

 

• V OBRY-ROGUET, S BRÉGIGEON, CE CANO, C LIONS, O ZAEGEL-FAUCHER, H LAROCHE, S GALIE, PG DE LAMARLIÈRE, M ORTICONI, MJ SOAVI, A SAOUT,  I POIZOT-MARTIN. Risk factors associated with overweight and obesity in HIV-infected people: Aging, behavioral factors but not cART in a cross-sectional study. Medicine (Baltimore). 2018;97:e10956. 

 

• I POIZOT-MARTIN, H LAROCHE, CE CANO, C NICOLINO-BRUNET,  O ZAEGEL-FAUCHER, S BREGIGEON, C TAMALET,  F DIGNAT-GEORGE. Cancer risk in HIV-infected patients: elite controllers are also concerned. AIDS. 2018 : 13;32:673-675.

 

 

• I POIZOT-MARTIN, V OBRY-ROGUET, O ZAEGEL-FAUCHER, C LIONS, C E. CANO, A IVANOVA, A S RITLENG, C DEBREUX, S BREGIGEON HIV infection and care pathway: From guidelines to clinical practice. Infection par le VIH et parcours de soin : des Recommandations à la Pratique Clinique Med Mal Infect. 2018 Sep 5. pii: S0399-077X(17)31022-3

 

• I POIZOT-MARTIN, E ROSENTHAL, C GILBERT, C CANO, A SIMON, C LASCOUX-COMBE, L ALRIC, A GERVAIS, DIDIER NEAU, L ESTERLE5, D SALMON, P SOGNI, L WITTKOP, for the ANRS CO13 HEPAVIH study group. Nadir CD4 is negatively associated with antinuclear antibody detection in HCV/HIV coinfected patients JAIDS (accepté en attente de publication) 

 

• P PUGLIESE, V JOLY, MA VALANTIN, L COTTE, T HULEUX , C ALLAVENA, J REYNES, I POIZOT-MARTIN, F BANI-SADR, L CUZIN L; Dat’AIDS group. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France. Med Mal Infect. 2018 Nov 5. pii: S0399-077X(17)30544-9. [Epub ahead of print]

 

• E  ROSENTHAL, C FOUGEROU-LEURENT, A RENAULT, MP CARRIERI, F MARCELLIN, R GARRAFFO, E TEICHER, H AUMAITRE, K LACOMBE, F BAILLY, E BILLAUD, S CHEVALIEZ, S DOMINGUEZ, MA VALANTIN, J REYNES, A NAQVI, L COTTE, S METIVIER, V LEROY, M DUPON, T ALLEGRE, P DE TRUCHIS, V JEANTILS, J CHAS, D SALMON-CERON, P MORLAT, D NEAU, P PERRE, L PIROTH, S POL, M BOURLIERE, GP PAGEAUX, L ALRIC, D ZUCMAN, PM GIRARD, I  POIZOT-MARTIN, Y YAZDANPANAH, FRAFFI, PEL ABIC, C TUAL, A PAILHE, I AMRI, E BELLISSANT,JM  MOLINA; ANRS HC31 SOFTRIH STUDY GROUP. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Med. 2018 Mar;19:227-237 (SCI IF :  3.257) L CUZIN, Y YAZDANPANAH, T HULEUX, L COTTE, P PUGLIESE, C ALLAVENA, J REYNES, I POIZOT-MARTIN, F BANI-SADR, C DELPIERRE; DAT'AIDS STUDY GROUP. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France. HIV Med. 2018;19:238-242 (SCI IF :  3.257)

 

• ALLAVENA C, HANF M, REY D, DUVIVIER C, BANISADR F, POIZOT-MARTIN I, JACOMET C, PUGLIESE P, DELOBEL P, KATLAMA C, JOLY V, CHIDIAC C, DOURNON N, MERRIEN D, MAY T, REYNES J, GAGNEUX-BRUNON A, CHIROUZE C, HULEUX T, CABIE A, RAFFI F; Dat’AIDS study group. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. PLoS One. 2018 ;13(9):e0203895

 

• CLIFFORD GM, SIPROUDHIS L, PIROTH L, POIZOT-MARTIN I, RADENNE S, REYNES J, LESAGE A, HEARD I, HENNO S, FLÉJOU JF, MARCHAND L, COMBES JD, ETIENNEY I; ANRS EP57 APACHES Study group. Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM. AIDS. 2018 Oct 23;32(16):2363-2371. doi: 10.1097/QAD.0000000000001947

 

• A MAKINSON, M HAYOT, S EYMARD-DUVERNAY, C RIBET, F RAFFI, G PIALOUX, D ZUCMAN, I POIZOT-MARTIN, F BONNET, S ABGRALL, P TATTEVIN, A CHERET, T FERRY, JM MAUBOUSSIN, L MARCHAND, C ROUZAUD, J REYNES, M ZINS, V LE MOING; ANRS EP48 HIV CHEST STUDY TEAM.

HIV is associated with airway obstruction: a matched controlled study.AIDS. 2018;32:227-232.

 

• J-D COMBES, I HEARD, I POIZOT-MARTIN, A CANESTRI, A LION, L PIROTH, J-M DIDELOT, T FERRY, O PATEY11, Lucie MARCHAND1, G M. CLIFFORD, I ETIENNEY; for the ANRS EP57 APACHES Study group Prevalence and risk factors for anal human papillomavirus infection in HIV-positive men having sex with men Journal of Infectious Diseases Jan 31. doi: 10.1093/infdis/jiy059. [Epub ahead of print]

 

• A GOBERT, M VEYRI, I POIZOT-MARTIN, A LAVOLÉ, C SOLAS, R PALICHE R, C KATLAMA, D COSTAGLIOLA, JP SPANO. HIV and cancer : What's new in 2017? Bull Cancer. 2018;105:256-262

 

• L CUZIN, Y YAZDANPANAH, T HULEUX, L COTTE, P PUGLIESE, C ALLAVENA, J REYNES, I POIZOT-MARTIN, F BANI-SADR, C DELPIERRE; DAT'AIDS STUDY GROUP. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France. HIV Med. 2018;19:238-242 (SCI IF :  3.257)

 

• P PRADAT, T HULEUX, F RAFFI, P DELOBEL, MA VALANTIN, I POIZOT-MARTIN, P PUGLIESE, J REYNES, D REY, B HOEN, A CABIE, F BANI-SADR, A CHERET, C DUVIVIER, C JACOMET, A FRESARD, L HUSTACHE-MATHIEU, L COTTE; Dat’AIDS study Group. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS. 2018 Feb 12. doi: 10.1097 [Epub ahead of print]

 

• A PROVOOST,  M DRAME, L COTTE,  L CUZIN, R GARRAFFO.R,  D REY, F RAFFI, I  POIZOT-MARTIN, P PUGLIESE,  F BANISADR Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV co-infection in a French Nationwide HIV cohort Alimentary Pharmacology & Therapeutics (accepté en attente de soumission)

 

• M HENTZIEN, A CABIE, P PUGLIESE, É BILLAUD, I POIZOT‐MARTIN, C DUVIVIER, M‐A VALANTIN, A KALADJIAN, M DRAMÉ, F BANI‐SADR, The Dat'AIDS Study Group Factors associated with deaths from suicide in a French nationwide HIV‐infected cohort HIV Medicine (accepté en attente de publication)

 

2017

 

• N CLOAREC,  C  SOLAS, A LADAIQUE, C TAMALET, O ZAEGEL-FAUCHER, S BREGIGEON, B CANET, CE CANO, I POIZOT-MARTIN Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases. Eur J Clin Pharmacol. 2017;73:1331-1333

 

• S BREGIGEON, A GALINIER , O ZAEGEL-FAUCHER, CE CANO , V OBRY, H LAROCHE, S TRIJAU , A SAOUT A, I POIZOT-MARTIN.  Frailty in HIV infected people: a new risk factor for bone mineral density loss.  AIDS. 2017; 17;31:1573-1577. (SCI IF : 5.003)

 

• S BREGIGEON, C SOLAS, O FAUCHER, V OBRY-ROGUET, C TAMALET, I POIZOT-MARTIN, Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration. Antivir Ther. 2017;22:529-533. (SCI IF : 2.594)

 

• C SOLAS, S BREGIGEON, O FAUCHER-ZAEGEL, S QUARANTA,V OBRY-ROGUET, C TAMALET, B LACARELLE, and I POIZOT-MARTIN Ledipasvir and Tenofovir drug interaction in HIV-HCV co-infected patients: Impact on Tenofovir Ctrough but not on Renal Safety? Br J Clin Pharmacol. 2018 ;84:404-409. (SCI IF : 3.493) F KHELOUFI, I POIZOT-MARTIN, R GARRAFFO, A TAVENARD, S QUARANTA A RENAULT, T LAVRUTE, M BOURLIERE, P HALFON, L PIROTH, E BELLISSANT, B LACARELLE, J-M MOLINA, C SOLAS AND THE ANRS HC27 BOCEPREVIH STUDY GROUP. ITPA deficiency and ribavirin level are still predictive of anemia in HCV-HIV co-infected patients receiving ribavirin combined to first generation DAA (ANRS HC27 BOCEPREVIH study). Antivir Ther. 2017;22:461-469. (SCI IF: 3.1)

 

• L CUZIN, C KATLAMA, L COTTE, P PUGLIESE, A CHERET, C BERNAUD, D REY, I POIZOT-MARTIN, C CHIROUZE, F BANI-SADR, A CABIÉ, for the Dat’AIDS Study Group*. Ageing with HIV: do comorbidities and poly-medication drive treatment optimization? Running head: HIV, co-morbidities and co-medications. HIV Med 2017, 18, 395-401 (SCI IF :  3.257)

 

• B SPIRE, L NAIT-IGHIL, P PUGLIESE, I POIZOT-MARTIN, V JULLIEN, A-G MARCELIN, ERIC BILLAUD Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. HIV Clin Trials. 2017;18:1-16. (SCI IF :  1.778)

 

• V POURCHER, A DESNOYER, L ASSOUMOU, C LEBBÉ ,  A CURJOL, AG MARCELIN AG, F CARDON, S GIBOWSKI, D SALMON, JM CHENNEBAULT, I POIZOT-MARTIN, G PEYTAVIN, F BOUÉ, D COSTAGLIOLA. Phase II trial of lenalidomide in HIV-infected patients with previously treated Kaposi's sarcoma: Results of the ANRS 154 Lenakap Trial. AIDS Res Hum Retroviruses. 2017 Jan;33:1-10. (SCI IF : 2.095 )

 

• A TATON, P COLSON, C DHIVER, J-M RUIZ, S BREGIGEON, C TOMEI, E RESSIOT,A MENARD, I POIZOT-MARTIN, I RAVAUX,  B LACARELLE AND C SOLAS Daclatasvir plasma concentration assessment in HIV-HCV co-infected real-life patients Antivir Ther. 2017;22(8):731-733. (SCI IF :2.594   )

 

• L PIROTH, L WITTKOP, K LACOMBE, E ROSENTHAL, C GILBERT, P MIAILHES, P CARRIERI, J CHAS, I POIZOT-MARTIN, A GERVAIS,  S DOMINGUEZ, D NEAU, D ZUCMAN, E BILLAUD, P MORLAT, H AUMAITRE, C LASCOUX-COMBE, A SIMON, O BOUCHAUD, E TEICHER, F BANI-SADR, L ALRIC, D VITTECOQ, F BOUE, C DUVIVIER, MA VALANTIN, L ESTERLE, F DABIS, P SOGNI, D SALMON; ANRS CO13 HEPAVIH study group. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017. pii: S0168-8278:30107-1 (SCI IF : 12.486 )

 

•  L COTTE, T FERRY, P PUGLIESE, MA VALANTIN, C ALLAVENA, A CABIÉ, I POIZOT-MARTIN, D REY, C DUVIVIER, A CHERET, P DELLAMONICA, P  PRADAT, JJ PARIENTI ; Dat’AIDS study group. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLoS One. 2017; 2;12:e0170661. (SCI IF :  2.806)

 

• P PRADAT, P PUGLIESE, I POIZOT-MARTIN, MA VALANTIN, L CUZIN, J REYNES, E BILLAUD, T HULEUX, F BANI-SADR, D REY, A FRÉSARD, C JACOMET, C DUVIVIER, A CHERET, L HUSTACHE-MATHIEU, B HOEN, A CABIÉ, L COTTE; DAT’AIDS STUDY GROUP. Direct-Acting Antiviral Treatment against Hepatitis C Virus infection in HIV-Infected Patients - "En route for eradication"? J Infect. 2017;75:234-241 (SCI IF :4.201        )

 

• P GANTNER, L CUZIN, C ALLAVENA, A CABIE, P PUGLIESE ,  M-A VALANTIN , F BANI-SADR, V JOLY,T FERRY, I POIZOT-MARTIN, R GARRAFFO, G PEYTAVIN, S FAFI-KREMER, D REY on behalf of the Dat’AIDS study Group. Efficacy and safety of dolutegravir and rilpivirine dual therapy as 1 a simplification. HIV Med. 2017;18:704-708 (SCI IF :  3.257)

 

• P CARRIERI, C PROTOPOPESCU, F MARCELLIN, S ROSELLINI, L WITTKOP, L ESTERLE, DAVID ZUCMAN, F RAFFI, E ROSENTHAL, I POIZOT-MARTIN, D SALMON- CÉRON; F DABIS; B SPIRE Protective Effect of Coffee Consumption on All-cause Mortality of French HIV-HCV Co-infected Patients (ANRS CO13 HEPAVIH Cohort). J Hepatol. 2017: 67/1157-1167 (SCI IF : 12.486 )

 

• F RAFFI, M HANF, T FERRY, L KHATCHATOURIAN, V JOLY, P PUGLIESE, CHRISTINE KATLAMA8,9, OLIVIER ROBINEAU10, C CHIROUZE, C JACOMET, P DELOBEL, I POIZOT-MARTIN, I RAVAUX, C DUVIVIER, A GAGNEUX-BUGNON, D REY, J REYNES, T MAY, F´ BANI-SADR, B HOEN, M MORRIER, A CABIE AND C ALLAVENA* on behalf of the Dat’AIDS Study Group† Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. J Antimicrob Chemother. 2017;72:3502 (SCI IF : 5.071 )

 

• C PROTIERE, B SPIRE, M MORA, I POIZOT-MARTIN, M PREAU, P MORLAT, D ZUCMAN, C GOUJARD, F RAFFI, O LAMBOTTE, M S MONTI Patterns of patients and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. PLoS One. 2017;12(11) (SCI IF :  2.806)

 

• V VIRLOGEUX, F ZOULIM, P PUGLIESE, I POIZOT-MARTIN, M-A VALANTIN, L CUZIN, J REYNES, E BILLAUD, T HULEUX, F BANI-SADR, D REY, A FRESARD, C JACOMET, C DUVIVIER,  A CHERET, L HUSTACHE-MATHIEU, B HOEN; A CABIE, L COTTE Modeling HIV-HCV coinfection epidemiology in the DAA era: the road to elimination. BMC Med. 2017;15:217   (SCI IF : 7.901)

 

• L CUZIN, P PUGLIESE, C ALLAVENA, D REY, C CHIROUZE, F BANI-SADR,  A CABIE, T HULEUX, I POIZOT-MARTIN, L COTTE, C ISNARD BAGNIS, P FLANDRE; DAT’AIDS STUDY GROUP. Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study. PLoS One. 2017;12:e0187517 (SCI IF :  2.806)

 

• L CUZIN, Y YAZDANPANAH, T HULEUX, L COTTE, P PUGLIESE, C ALLAVENA, J REYNES, I POIZOT-MARTIN, F BANI-SADR, C DELPIERRE; DAT'AIDS STUDY GROUP. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France. HIV Med. 2018;19:238-242 (SCI IF :  3.257)

 

2016

 

• I POIZOT-MARTIN,  C ALLAVENA, C DUVIVIER, CE CANO, F GUILLOUET DE SALVADOR, D REY, P DELLAMONICA, L CUZIN, A CHERET, B HOEN; DAT'AIDS STUDY GROUP. CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART. PLoS One. 2016;8;11:e0165774.

 

• I POIZOT-MARTIN, C ALLAVENA, C DELPIERRE, C  DUVIVIER, V OBRY-ROGUET, CE CANO, F GUILLOUET DE SALVADOR, D REY, P DELLAMONICA, A CHERET, L CUZIN, C KATLAMA, A CABIÉ, B HOEN; DAT’AIDS STUDY GROUP. First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. Medicine (Baltimore). 2016;95:e5087.

 

• I POIZOT-MARTIN, S BRÉGIGEON,  C TAMALET, R BOUABDALLAH, O ZAEGEL-FAUCHER, V OBRY-ROGUET, A IVANOVA, CE  CANO, C SOLAS . A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety. Case Rep Oncol Med.2016:8515218.

 

• L COTTE, P PUGLIESE, MA VALANTIN, L CUZIN, E BILLAUD,  C DUVIVIER, A NAQVI, A CHERET, D REY, P PRADAT, I POIZOT-MARTIN; DAT’AIDS STUDY GROUP. Hepatitis C treatment initiation in HIV-HCV coinfected patients. BMC Infect Dis. 2016; 22;16:345.

 

• I POIZOT-MARTIN, E BELLISSANT, R GARRAFFO, P COLSON, L PIROTH, C SOLAS C, RENAULT A, BOURLIÈRE M, HALFON P, GHOSN J, ALRIC L, NAQVI A, CARRIERI P, MOLINA JM; ANRS HC27 BOCEPREVIH Study Group. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. HIV Clin Trials. 2016;17:63-71.

 

• I POIZOT-MARTIN, C ALLAVENA, C DELPIERRE, C DUVIVIER, V OBRY-ROGUET, C.E. CANO, F GUILLOUET DE SALVADOR, D REY, P DELLAMONICA, A CHERET, L CUZIN, C KATLAMA, A CABIÉ1, B HOEN for the Dat’AIDS Study Group. Impact of first-line cART Regimen on the dynamic of CD8+ T-cell counts in patients achieving sustained undetectable HIV viral load. Medicine (Baltimore). 2016;95:e5087. (SCI IF : 5.723)

 

• JP SPANO , I POIZOT-MARTIN, D COSTAGLIOLA, F BOUÉ, O ROSMORDUC, A LAVOLÉ, S CHOQUET, PE HEUDEL, V LEBLOND, J GABARRE, MA VALANTIN, C SOLAS, A GUIHOT, G CARCELAIN, B AUTRAN, C KATLAMA, L QUÉRO. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol. 2016;27:397-408.

 

• I HEARD, I POIZOT-MARTIN, V POTARD, I ETIENNEY, C CRENN-HEBERT, C MOORE, P TOURAINE,H CUBIE, D COSTAGLIOLA; ANRS-C017 VIHGY Study Group. Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era.

J Infect Dis. 2016;213:1455-61.

 

• A MAKINSON, S EYMARD-DUVERNAY, F RAFFI, S ABGRALL, S BOMMART, D ZUCMAN, F VALOUR, A CHERET, I POIZOT-MARTIN, C DUVIVIER, JM MAUBOUSSIN, F BONNET, P TATTEVIN, J REYNES, V LE MOOING Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. The ANRS EP48 HIV VHEST Study. AIDS. 2016;30:573-82. SCI IF:4.407)

 

• F MARCELLIN, I FOURNIER, M P CARRIERI, I POIZOT-MARTIN, L COTTE and the ANRS HC26 & ANRS HC27 Study Groups From first-generation HCV protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials). Eur J Gastroenterol Hepatol. 2016 ;28:733-4  (SCI IF 2.093)

 

• C ALLAVENA, C KATLAMA, L COTTE , PM ROGER, P DELOBEL, A CHERET, DUVIVIER C, I POIZOT-MARTIN, B HOEN, A CABIE, A CHERET, R LAHOULOU, F RAFFI, P PUGLIESE; DAT’AIDS STUDY GROUP. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.Infect Dis (Lond). 2016; 13:1-7

 

• F MARCELLIN, C PROTOPOPESCU, I POIZOT-MARTIN, P MIAILHES, L  ESTERLE, L WITTKOP, B SPIRE, A BOCQUIER, D SALMON-CERON, F DABIS, M P CARRIERI & the HEPAVIH ANRS CO13 Study Group* Fatigue in the long term after HCV treatment in HIV-HCV co-infected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin containing regimens (ANRS CO13-HEPAVIH cohort). Eur J Gastroenterol Hepatol. 2016;28:1003-7. (SCI IF: 2,25).

 

• P SOGNI, C GILBERT, K LACOMBE, L PIROTH, E ROSENTHAL, P MIAILHES, A GERVAIS, L ESTERLE, J CHAS, I POIZOT-MARTIN, S DOMINGUEZ, A SIMON, P MORLAT, D NEAU, D ZUCMAN, O BOUCHAUD, C LASCOUX-COMBE, F BANI-SADR, L ALRIC, C GOUJARD, D VITTECOQ, E BILLAUD, H AUMAÎTRE, F BOUÉ, MA VALANTIN , F DABIS, D SALMON, L WITTKOP. All-oral DAA regimens in HIV-HCV coinfected cirrhotic patients are efficient and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort. Clin Infect Dis. 2016;63:763-70  (SCI IF : 8.886)

 

• L MICHEL, C LIONS, M WINNOCK, JP LANG , MA LOKO, E ROSENTHAL, B MARCHOU, MA VALANTIN , P MORLA, P ROUX, P SOGNI, B SPIRE, I POIZOT-MARTIN, K LACOMBE, C LASCOUX-COMBE, C DUVIVIER, F NEAU D, DABIS, D SALMON-CERON, MP CARRIERI; ANRS HEPAVIH CO13 study group. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]. HIV Med. 2016;17:758-765

 

• A MAKINSON, V LE MOING, J REYNES, T FERRY, A LAVOLE, I POIZOT-MARTIN, JL  PUJOL, JP SPANO, B MILLERON. Lung Cancer Screening with Chest Computed Tomography in People Living with HIV. A Review by the Multidisciplinary CANCERVIH Working Group.J Thorac Oncol. 2016;11:1644-52

 

• F KHELOUFI, E BELLISSANT, L COTTE, I POIZOT-MARTIN, S QUARANTA, R GARRAFFO, A BARRAIL-TRAN, A RENAULT, I FOURNIER, B LACARELLE, M BOURLIÈRE, JM MOLINA, C SOLAS; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH STUDY GROUPS. Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. AIDS. 2016.24;30:2085-90. (SCI IF: 4.407)

 

• D SALMON, C GILBERT, E ROSENTHAL, P MIAILHES, J CHAS, K LACOMBE, POIZOT-MARTIN I, A GERVAIS, P SOGNI, P WITTKO Pour la Cohorte L; ANRS CO13 HEPAVIH. HEP-14 - Caractéristiques des patients en échec de traitement par combinaisons d'antiviraux à action directe (AAD) chez les patients co-infectés VIH/VHC. Med Mal Infect. 2016;46(4 Suppl 1):55.

 

• P DE BOISSIEU, M DRAME, F RAFFI, A CABIE, I POIZOT-MARTIN, L COTTE L, P DELOBEL, T HULEUX, D REY,  FBANI-SADR F. COL 3-04 - Abacavir/lamivudine/nevirapine comparée aux trithérapies classiques dans la cohorte Dat'AIDS : efficacité virologique similaire et meilleure tolérance à long terme. Med Mal Infect. 2016;46(4 Suppl 1):6.

 

• P DE BOISSIEU, M DRAME, F RAFFI, A CABIE, I POIZOT-MARTIN, L COTTE L, P DELOBEL, T HULEUX, D REY,  FBANI-SADR F.; Dat’AIDS Study Group. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study. Medicine (Baltimore). 2016;95 :e4890

 

• L COTTE, P PUGLIESE, MA VALANTIN , L CUZIN, E BILLAUD, C DUVIVIER, A NAQVI, A CHERET, D REY, P PRADAT P, I POIZOT-MARTIN; Dat’AIDS study Grou. Hepatitis C treatment initiation in HIV-HCV coinfected patients. BMC Infect Dis. 2016;22;16:345.  (SCI IF 2.825)

 

2015

 

• O FAUCHER, S BREGIGEON, C CANO, V OBRY ROGUET, C NICOLINO BRUNET, C TAMALET, F DIGNAT-GEORGES, I POIZOT-MARTIN Impact of HCV co-infection on T cell dynamics in long term HIV-suppressors under Cart. AIDS. 2015;29:1505-10

 

• I POIZOT-MARTIN, A NAQVI, V OBRY-ROGUET, M-A VALANTIN, L CUZIN; E BILLAUD, A CHERET, D REY,  C JACOMET, C DUVIVIER, P PUGLIESE, P PRADAT, L COTTE. Potential for Drug-drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. PLoS One. 2015 , 21;10:e0141164

 

• I HEARD, I ETIENNEY, V POTARD, I POIZOT-MARTIN, C MOORE, AC LESAGE, E RESSIOT , C CRENN-HEBERT , FJ FLÉJOU , H CUBIE, D COSTAGLIOLA, TM DARRAGH ; for the ANRS-C017 VIHGY Study Group. High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women.. Clin Infect Dis. 2015;60:1559-68.

 

• MP CARRIERI, L SERFATY, A VILOTITCH, M WINNOCK, I POIZOT-MARTIN, MA LOKO, C LIONS, C LASCOUX-COMBE, P ROUX, D SALMON-CERON, B SPIRE, F DABIS; ANRS CO13 HEPAVIH STUDY GROUP. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015 Mar 16. pii: civ217.

 

• H HAJJI, S AHERFI, A MOTTE, I RAVAUX, S MOKHTARI, JM RUIZ, I POIZOT-MARTIN, C TOURRES, N TIVOLI, R GEROLAMI, C TAMALET, P COLSON Diversity of 1,2,3 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille University Hospitaln southeastern France. J Med Virol 2015:1921-33

 

• D SALMON, P SOGNI, C GILBERT, F BANI-SADR, E ROSENTHAL, I POIZOT-MARTIN, C KATLAMA , K LACOMBE, A GERVAIS, C DUVIVIER, C LASCOUX, D NEAU, J CHAS, S DOMINGUEZ, P MORLAT, M-A LOKO, P CARRIERI, F DABIS, and L WITTKOP Regression of liver stiffness after sustained HCV virological responses among HIV/HCV-coinfected patients -The ANRS CO13 HEPAVIH cohort*. AIDS. 2015;29:1821-30

 

2014

 

• N CLOAREC, O ZAEGEL-FAUCHER, S BREGIGEON, CE CANO, C CHOSSEGROS, B WAJSZCZAK,  I POIZOT-MARTIN. Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient: case report and review of the literature.AIDS. 2014;28;28:448-50. (SCI IF : 5.554 )

 

• C TAMALET, V OBRY-ROGUET, E RESSIOT, S BREGIGEON, J DELGRANDE, and I POIZOT-MARTIN.  Distribution of Human Papillomavirus Genotypes, Assessment of HPV 16 and 18 Viral Load and Anal Related Lesions in HIV Positive Patients:A Cross- Sectional Analysis. J Med Virol. 2014; 86:419-25.  (SCI IF :2.373)

 

• V BERGAMASCHI, O FAUCHER, E RESSIOT, S BREGIGEON, V OBRY, C TAMALET, I POIZOT-MARTIN  Impact de la charge virale HPV16 dans l'évolution d'une dysplasie anale.(C-08). Med Mal Infect. 2014:33. doi: 10.1016 (SCI IF :0.846)

 

• C TAMALET, V OBRY-ROGUET, E RESSIOT, S BREGIGEON, J DELGRANDE, and I POIZOT-MARTIN. Distribution of Human Papillomavirus Genotypes, Assessment of HPV 16 and 18 Viral Load and Anal Related Lesions in HIV Positive Patients:A Cross-Sectional Analysis. J Med Virol. 2014; 86:419-25. (SCI IF :2.373)

 

• JP SPANO, I POIZOT-MARTIN, L QUERO Cancer and HIV Bull Cancer. 2014;101:994-6. (SCI IF: 0.635)

 

• V POTARD, D REY, I POIZOT-MARTIN, S MOKHTARI, C PRADIER, W ROZENBAUM, F BRUN-VEZINET, D COSTAGLIOLA; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4).Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. J Int AIDS Soc. 2014;17:19070.

 

• S AHERFI, C SOLAS, A MOTTE, J MOREAU, P BORENTAIN, M MOKHTARI, D BOTTA-FRIDLUND, C DHIVER, I PORTAL, JM RUIZ, I RAVAUX, S BREGIGEON, I POIZOT-MARTIN, A STEIN, R GEROLAMI, P BROUQUI, CTAMALET, P COLSON Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. J Med Virol. 2014;86:1868-76.

 

• A GOBERT, N MOUNIER, A LAVOLE, I POIZOT-MARTIN, JP SPANO HIV-related malignancies: state od art.  Bull Cancer. 2014;101:1020-9. 

 

• BK TAN, C GILBERT, F BOCCARA, P MORLAT, I POIZOT-MARTIN, P SOGNI, D SALMON. B-04: Les niveaux de LDL-cholestérol et de triglycérides sont des facteurs prédictifs indépendants d'évènements cardiovasculaires chez les patients co-infectés VIH-VHC : cohorte HEPAVIH-ANRS CO13. Med Mal Infect. 2014:30. doi: 10.1016

 

 

• P CACOUB, A ELMALEH-SACHS1, I POIZOT-MARTIN, C GOUJARD, P MIAILHES, P MORLAT, J CHAS, I GODEREL. Changes in the Profile and Care of HIV-HCV Seropositive Patients in Two Cross-Sectional Surveys in France (2006 and 2013) Pol16, Eric Rosenthal17 and The GERMIVIC Study Group18. AIDS Research;  J AIDS Clin Res 2014, 5:12

 

• FAUCHER, S BREGIGEON, C CANO, V OBRY ROGUET, C NICOLINO BRUNET, C TAMALET, F DIGNAT-GEORGES, I POIZOT-MARTIN Impact of HCV co-infection on T cell dynamics in long term HIV-suppressors under Cart. AIDS  2015 (sous presse)

 

• I HEARD, I ETIENNEY, V POTARD, I POIZOT-MARTIN, C MOORE, AC LESAGE, E RESSIOT , C CRENN-HEBERT , FJ FLÉJOU , H CUBIE, D COSTAGLIOLA, TM DARRAGH ; for the ANRS-C017 VIHGY Study Group. High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women.. Clin Infect Dis. 2015;60:1559-68.

 

• MP CARRIERI, L SERFATY, A VILOTITCH, M WINNOCK, I POIZOT-MARTIN, MA LOKO, C LIONS, C LASCOUX-COMBE, P ROUX, D SALMON-CERON, B SPIRE, F DABIS; ANRS CO13 HEPAVIH STUDY GROUP.Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015 Mar 16. pii: civ217.

 

• MIAILHES, P MORLAT, J CHAS, I GODEREL. Changes in the Profile and Care of HIV-HCV Seropositive Patients in Two Cross-Sectional Surveys in France (2006 and 2013) Pol16, Eric Rosenthal17 and The GERMIVIC Study Group18. AIDS Research  ( 2015, sous presse)

 

• JP SPANO, I POIZOT-MARTIN, L QUERO Cancer and HIV Bull Cancer. 2014;101:994-6

 

• C TAMALET, V OBRY-ROGUET, E RESSIOT, S BREGIGEON, J DELGRANDE, and I POIZOT-MARTIN.  Distribution of Human Papillomavirus Genotypes, Assessment of HPV 16 and 18 Viral Load and Anal Related Lesions in HIV Positive Patients:A Cross- Sectional Analysis. J Med Virol. 2014; 86:419-25

 

• N CLOAREC, O ZAEGEL-FAUCHER, S BREGIGEON, C. E CANO, C CHOSSEGROS, I POIZOT-MARTIN. Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient. AIDS. 2014; 28:448-450

 

• V POTARD, D REY, I POIZOT-MARTIN, S MOKHTARI, C PRADIER, W ROZENBAUM, F BRUN-VEZINET, D COSTAGLIOLA; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4).Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.J Int AIDS Soc. 2014;17:19070

 

• BERGAMASCHI, O FAUCHER, E RESSIOT, S BREGIGEON, V OBRY, C TAMALET, I POIZOT-MARTIN  Impact de la charge virale HPV16 dans l'évolution d'une dysplasie anale.(C-08)Med Mal Infect. 2014:33. doi: 10.1016

 

• I POIZOT-MARTIN, C GILBERT, E TEICHER, G PIALOUX, P SOGNI, L WITTKOP, D SALMON-CERON.Accès à la transplantation hépatique (TH) chez les patients (pts) coinfectés VIH-VHC de la cohorte ANRSCO13 HEPAVIH. (COL01-04)Med Mal Infect. 2014;44:2. doi: 10.1016

 

• S AHERFI, C SOLAS, A MOTTE, J MOREAU, P BORENTAIN, M MOKHTARI, D BOTTA-FRIDLUND, C DHIVER, I PORTAL, JM RUIZ, I RAVAUX, S BREGIGEON, I POIZOT-MARTIN, A STEIN, R GEROLAMI, P BROUQUI, CTAMALET, P COLSON Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. J Med Virol. 2014;86:1868-76

 

• A GOBERT, N MOUNIER, A LAVOLE, I POIZOT-MARTIN, JP SPANO HIV-related malignancies: state od art.  Bull Cancer. 2014;101:1020-9

 

• C ALLAVENA, C KATLAMA, L COTTE L, PM ROGER, P DELOBEL, A CHERET, C DUVIVIER, I POIZOT-MARTIN, B HOEN, A CABIÉ, A CHERET, R LAHOULOU, F RAFFI, P PUGLIESE. Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort.J Int AIDS Soc. 2014;2;17:19780

 

• BK TAN, C GILBERT, F BOCCARA, P MORLAT, I POIZOT-MARTIN, P SOGNI, D SALMON. Les niveaux de LDL-cholestérol et de triglycérides sont des facteurs prédictifs indépendants d'évènements cardiovasculaires chez les patients co-infectés VIH-VHC : cohorte HEPAVIH-ANRS CO13. Med Mal Infect. 2014:30. doi: 10.1016

 

• I POIZOT-MARTIN, O FAUCHER, V OBRY-ROGUET, C NICOLINO-BRUNET, S RONOT-BREGIGEON, F DIGNAT-GEORGE, C TAMALET. Lack of correlation between the size of HIV Proviral DNA Reservoir and the level of Immune activation in HIV- infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol. 2013; 57: 351-5

 

• L CUZIN, C ALLAVENA , P PUGLIESE, D REY, B HOEN ,I  POIZOT-MARTIN, A CABIE, Y YAZDANPANAH ; DATʼAIDS Study Group. Can the "seek, test, treat, and retain" strategy be effective in France?J Acquir Immune Defic Syndr. 2013;62(4):e119-21

 

• LAUNAY , M SURENAUD, C DESAINT , N BEN HAMOUDA , G PIALOUX , B BONNET, I POIZOT-MARTIN,G  GONZALES, L CUZIN , I BOURGAULT-VILLADA ,Y  LEVY, J CHOPPIN , C DURIER. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013;31:4406-15

 

• P COLSON , S BREGIGEON, C TOURRES , C SOLAS, I POIZOT-MARTIN , C TAMALET. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. J Clin Virol. 2013;58:309-14

 

• JM CHAPPLAIN, E BELLISSANT, D GUYADER, JM MOLINA, I POIZOT-MARTIN, P PERRE, G PIALOUX, B TURLIN, C MOUCHEL, A RENAULT, C MICHELET; ANRS HC-12 Study Group. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial. J Infect. 2013;67:313-21

 

• I POIZOT-MARTIN , O FAUCHER , V OBRY-ROGUET, C NICOLINO-BRUNET , S RONOT-BREGIGEON , F DIGNAT-GEORGE , C TAMALET . Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol. 2013;57:351-5

 

• P PUGLIESE, C  DELPIERRE, L CUZIN , I POIZOT-MARTIN , D REY, K SAUNE , J COTTALORDA, D BETTINGER, C DELAUGERRE, B HOEN; Dat AIDS Study Group. An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. HIV Med. 2013;14:509-15

 

• JJ ERON, B CLOTET, J DURANT, C KATLAMA , P KUMAR,  A LAZZARIN, I POIZOT-MARTIN, G RICHMOND, V SORIANO , M AIT-KHALED, T FUJIWARA,J  HUANG,  S MIN, C VAVRO , J YEO ; VIKING Study Group. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207:740-8

 

• S PERRIN , J CREMER, O FAUCHER, J REYNES, P DELLAMONICA, J MICALLEF, C SOLAS , B LACARELLE, C STRETTI, E KASPI , A ROBAGLIA-SCHLUPP , C NICOLINO-BRUNET, C TAMALET, N LÉVY, I  POIZOT-MARTIN , P CAU , P ROLL . HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.PLoS One. 2012;7:e53035

 

• I POIZOT-MARTIN, C SOLAS, J ALLEMAND, V OBRY-ROGUET, V PRADEL, S  BREGIGEON, O FAUCHER, B LACARELLE. Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration.  J Acquir Immune Defic Syndr. 2012 ; 62:375-80

 

• V COLOMBIE, S PUGLIESE-WEHRLEN, S DEUFFIC-BURBAN, L  CUZIN, P PUGLIESE, C KATLAMA , I POIZOT-MARTIN, RAFFI F, CABIE A, DELLAMONICA P, YAZDANPANAH Y; Dat'Aids. Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription. Int J STD AIDS. 2012;23:865-9

 

• S PERRIN , J CREMER, P ROLL , O FAUCHER, A MÉNARD, j REYNES, p DELLAMONICA, A NAQVI, J MICALLEF,E  JOUVE,  C TAMALET, C SOLAS, C PISSIER, I ARNOUX ,C  NICOLINO-BRUNET , L ESPINOSA, N LÉVY, E KASPI, A ROBAGLIA-SCHLUPP, I POIZOT-MARTIN, P CAU . HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" study. PLoS One. 2012;7:e41129

 

• C SOLAS, E PAMBRUN, M WINNOCK, D SALMON, I POIZOT-MARTIN , S DOMINGUEZ, F BANI-SADR, J IZOPET, R GARRAFFO , G PEYTAVIN; Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? ANRS CO-13 HEPAVIH Study Group.  AIDS. 2012;26:2193-9

 

• MP LÊ, C  SOLAS, R GARRAFFO , MC  GAGNIEU, P MURET , P YENI , C DHIVER, C  KATLAMA, I POIZOT-MARTIN I, DURANT J, PEYTAVIN G. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor. J Antimicrob Chemother. 2012;67:2779-81

 

• D SALMON-CERON, J COHEN, M WINNOCK, P ROUX, FB SADR, E  ROSENTHAL, I POIZOT- MARTIN, MA LOKO, M MORA, P SOGNI , B SPIRE , F DABIS, MP  CARRIERI ; HEPAVIH group. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res. 2012;12:59

 

• S DOMINGUEZ, J GHOSN, B CASSARD, G MELICA, I POIZOT-MARTIN, C SOLAS, AS LASCAUX , M  BOUVIER-ALIAS,  C KATLAMA,  Y LÉVY, G PEYTAVIN. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. J Antimicrob Chemother. 2012;67:1449-52

 

• V BOURCIER, M WINNOCK, M AIT AHMED, P SOGNI, E PAMBRUN, I  POIZOT-MARTIN, C CHAFFAUT, S CHEVRET, JC TRINCHET , D SALMON; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol. 2012;36:214-21

 

• C ALLAVENA, P FLANDRE , P PUGLIESE, MA VALANTIN , I  POIZOT-MARTIN, A CABIÉ, H MELLIEZ, L CUZIN ,C  DUVIVIER , P DELLAMONICA , F RAFFI ; Dat'aids Group. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort. Scand J Infect Dis. 2012;44:37-43

 

• M KABA, H RICHET, I RAVAUX , J MOREAU,  I POIZOT-MARTIN , A MOTTE, C NICOLINO-BRUNET,  F DIGNAT-GEORGE, A MÉNARD, C DHIVER, P BROUQUI, P COLSON . Hepatitis E virus infection in patients infected with the human immunodeficiency virus. J Med Virol. 2011;83:1704-16

 

• P FLANDRE, P PUGLIESE, L CUZIN , CI BAGNIS , I TACK, A CABIÉ, I POIZOT-MARTIN , C KATLAMA , C BRUNET-FRANÇOIS, Y YAZDANPANAH , P DELLAMONICA; New AIDS Data group. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6:1700-7

 

• E LANOY, PS ROSENBERG, F FILY, AS LASCAUX, V MARTINEZ, M PARTISANI,  I POIZOT-MARTIN, E  ROUVEIX, EA ENGELS, D COSTAGLIOLA, JJ GOEDERT; FHDH-ANRS CO4. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.Blood. 2011;118:44-9

 

• A MAKINSON, JC TENON, S EYMARD-DUVERNAY, JL PUJOL,  C ALLAVENA,L  CUZIN, I POIZOT-MARTIN , X DE LA TRIBONNIERE, A CABIE, P PUGLIESE , J REYNES, V LE MOING. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol. 2011;6:1022-9

 

• E LANOY, M GUIGUET, M BENTATA, E ROUVEIX, C DHIVER, I POIZOT-MARTIN, DCOSTAGLIOLA, J GASNAULT; FHDH-ANRS CO4. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology. 2011 15;76:644-51

 

• E LANOY, JP SPANO , F BONNET, M GUIGUET , F BOUÉ, J CADRANEL, G CARCELAIN, LI  COUDERC, P FRANGE , PM  GIRARD, E OKSENHENDLER, I  POIZOT-MARTIN, C SEMAILLE, H AGUT , C KATLAMA, D  COSTAGLIOLA ; ONCOVIH study group. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer. 2011;129:467-75

 

• S GALLIEN, V JOURNOT, W ROZENBAUM, P YÉNI, P MORLAT, I POIZOT-MARTIN , J REYNES, V RELIQUET, P LECLERCQ, F SIMON , G CHÊNE, JM MOLINA; ALIZE (ANRS 099) Study Group. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).J Antimicrob Chemother. 2011;66:184-91

 

• P COLSON, C  DHIVER, I POIZOT-MARTIN , C  TAMALET, R GÉROLAMI. Acute and chronic hepatitis E in patients infected with human immunodeficiency virus. J Viral Hepat. 2011;18:227-8

 

• MA LOKO, D SALMON , P  CARRIERI , M WINNOCK ,M  MORA,  L MERCHADOU, S GILLET, E PAMBRUN, J  DELAUNE, MA VALANTIN , I POIZOT-MARTIN , D NEAU, P BONNARD , E ROSENTHAL, K BARANGE, P MORLAT, K LACOMBE, A GERVAIS, F ROUGES , AB SEE, C  LASCOUX-COMBE , D VITTECOQ , C GOUJARD , C DUVIVIER , B  SPIRE, J IZOPET, P SOGNI, L SERFATY, Y BENHAMOU, BF ANI-SADR , F DABIS ; ANRS CO 13 HEPAVIH Study Group. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis. 2010;10:303

 

• L BENTZ, P  ENEL, B DUNAIS , J DURANT, I POIZOT-MARTIN, C TOURETTE-TURGIS, M REBILLON, F LE DUFF, P DELLAMONICA, C PRADIER. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care. 2010;22:1509-16

 

• E FONTAS, I KOUSIGNIAN , C  PRADIER, I POIZOT-MARTIN , C DURIER, L WEISS, Y  LEVY, D COSTAGLIOLA; FHDH ANRS CO4; ANRS CO14.IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. J Antimicrob Chemother. 2010;65:2215-23

 

• D SALMON-CÉRON, C DURIER, C DESAINT, L CUZIN , M  SURENAUD, NB HAMOUDA, JD LELIÈVRE, B BONNET, G PIALOUX, I POIZOT-MARTIN, JP ABOULKER, Y LÉVY, O LAUNAY; ANRS VAC18 trial group. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS. 2010;24:2211-23

 

• L MICHEL, V VILLES , F DABIS , B SPIRE, M WINNOCK, MA  LOKO, I POIZOT-MARTIN, MA VALANTIN, P BONNARD, D SALMON-CÉRON, MP  CARRIERI; ANRS Co13 HEPAVIH Study Group. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008. J Viral Hepat. 2010;17:650-60

 

• I POIZOT-MARTIN. Antagonistes du CCR5 : apport d’une nouvelle classe d’antirétroviraux dans la prise en charge de l’infection par le VIH. Med Mal Infect. 2010;40:245-55